Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Stephen D. Wise"'
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 37:3-24
Ethnic differences in warfarin maintenance doses have been documented amongst the three major Asian ethnic groups (Chinese, Malay and Indian) in Singapore. Studies have shown that cytochrome P450 2C9 (CYP2C9) polymorphisms alone did not entirely acco
Publikováno v:
ASSAY and Drug Development Technologies. 7:80-89
Standard estrogenic prodrugs such as estradiol valerate (E2V) and increasingly popular phytoestrogen formulations are commonly prescribed to improve menopausal health. These drugs are metabolized to numerous bioactive compounds, known or unknown, whi
Autor:
Charles Flexner, Clark Chan, Lawrence S. Lee, Paul S. Lietman, Teresa L. Parsons, Stephen D. Wise
Publikováno v:
The Journal of Clinical Pharmacology. 48:599-609
Human immunodeficiency virus (HIV)-infected patients often take herbal medicines, which may interact with antiretrovirals. American ginseng induces phase 2 and antioxidant enzymes in vitro and might increase the clearance of zidovudine and/or enhance
Autor:
Amparo de la Peña, Mei T. Loh, Stephen D. Wise, Bernard L. Silverman, Kewee P. Yeo, Clark Chan, Douglas B. Muchmore, Alan X. Pan
Publikováno v:
British Journal of Clinical Pharmacology. 65:480-487
What is already known about this subject • Only one other study (Becker et al.) has reported on the influence of smoking cessation and smoking resumption on inhaled insulin pharmacokinetics and glucodynamics, concluding that the rapid changes assoc
Autor:
Stephen D. Wise, Helen B. Isaac, Shan Hong Huang, Ronan P. Kelly, Chung-Yung J. Lee, Barry Halliwell, Kwee Poo Yeo, Lorraine Teng
Publikováno v:
Free Radical Research. 42:514-522
Vitamin C is a potent antioxidant in vitro and has been reported to act as a vasodilator, possibly by increasing nitric oxide bioavailability. This study examined the antioxidant and vascular effects of a single large oral dose of vitamin C in 26 hea
Autor:
Mark E. Bangs, Yi M. Cui, Amanda J. Long, Eunice Yuen, Choo H. Teng, Ying Zhou, Alan X. Pan, Xia Zhao, Stephen D. Wise, Kwee P. Yeo
Publikováno v:
British Journal of Clinical Pharmacology. 64:445-449
What is already known about this subject • Atomoxetine is a cytochrome P450 2D6 (CYP2D6) substrate and its pharmacokinetics has been characterized in a predominantly White population during clinical development. • There are scant East Asian pharm
Autor:
Richard W. Peck, Alan Pan, Leyan Teng, Danny Soon, Kwee Poo Yeo, Stephen D. Wise, Stephen L. Lowe
Publikováno v:
Psychoneuroendocrinology. 31:473-484
The objective of the study was to assess l-5-hydroxytryptophan's (l-5HTP) augmentation effect on the neuroendocrine response to a SSRI (citalopram). A neuroendocrine challenge study was conducted in healthy Asian male subjects. The neuroendocrine res
Autor:
James Voelker, Stephen L. Lowe, Jennifer L. Burkey, Ming Tung Lim, Stephen D. Wise, Kwee Poo Yeo
Publikováno v:
British Journal of Clinical Pharmacology. 61:200-210
Aims The aim of this study was to evaluate the effect of rifampicin co-administration on the pharmacokinetics of ruboxistaurin and its active metabolite, N-desmethyl ruboxistaurin and, in addition, to compare the changes in pharmacokinetics of ruboxi
Autor:
Lorraine Teng, James Voelker, Stephen D. Wise, Eunice Yuen, Yeo Kwee Poo, Titus Lau, Clark Chan
Publikováno v:
Clinical Pharmacokinetics. 45:297-303
Ruboxistaurin, a specific inhibitor of the beta(1) and beta(2) isoforms of protein kinase C, is currently in clinical development for the treatment of several diabetic microvascular complications. The major metabolite, N-desmethyl ruboxistaurin (meta
Autor:
Adeline Yeo, Helle Linnebjerg, Prajakti A. Kothare, Maggie Lim, Soomin Park, Stephen D. Wise, Kenneth F. Mace, Danny Soon, Clark Chan
Publikováno v:
The Journal of Clinical Pharmacology. 45:1032-1037
This open-label study investigated the effect of exenatide coadministration on the steady-state plasma pharmacokinetics of digoxin. A total of 21 healthy male subjects received digoxin (day 1, 0.5 mg twice daily; days 2-12, 0.25 mg once daily) and ex